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The process of angiogenesis ensures the formation of the bloodstream at the site of its 
increased need. Therefore, it is not surprising that angiogenesis is often included in the tumor 
production process, because it provides the tumor cells nutrition supply and metabolite 
removal. The targeting of angiogenesis has become a key topic of some scientific research. 
The process of tumor blood supply formation provides a family of vascular endothelial factors 
(VEGFs) and their respective receptors, which have become the target of the angiogenesis 
attenuation in a cancer treatment. One of many therapeutics is the monoclonal antibody 
ramucirumab targeted against VEGF receptor type 2 (VEGFR-2). Radioactive labeling of 
ramucirumab with a suitable radionuclide could bring benefits in either radiotherapy or 
radiodiagnostics. 
The aim of this diploma thesis was the indirect radioactive labeling of monoclonal antibody 
ramucirumab using 99mTc as radiodiagnostic nuclide via the chelation agent succinimidyl-6-
hydrazinonicotinamide (HYNIC) with the subsequent determination of the radiochemical 
purity of the prepared radiopharmaceutical and particularly its ability to bind VEGFR-2 
expressed on human tumor cells followed by the cell internalization. Radiochemical purity 
was determined using the methods of iTLC and HPLC with the radiometric detection. The 
cell internalization was tested with the employment of the manual internalization technique 
and automatic radioimmunoassay with the real-time detection. 
The found results showed that the indirect radioactive labeling of monoclonal antibody 
ramucirumab with the radiodiagnostic nuclide 99mTc resulted in the radiochemical purity over 
99 %. Furthermore, the very good stability of the prepared radioligand was verified for 24 
hours. The results of the internalization on two human tumor cell lines confirmed the 
maintenance of 99mTc HYNIC-ramucirumab binding to the targeted cellular VEGFR-2. 
The found results confirmed the possibility of monoclonal antibody ramucirumab 
radiolabeling with 99mTc via the chelating agent HYNIC. The binding ability of the 
radiolabeled antibody to VEGFR-2 was maintained. Thanks to these findings, the prepared 
radiopharmaceutical could serve as a promising radiodiagnostic ligand. 
 
